KIORA PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
KIORA PHARMACEUTICALS, INC. (KPRX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 0.00% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-03-25
- KIORA PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was 0.00%.
- KIORA PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was -3.49%.
- KIORA PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2024-12-31 | 0.00% 10-K · filed 2025-03-25 |
| 2023-12-31 | -3.49% 10-K · filed 2025-03-25 |
| 2022-12-31 | 0.00% 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |